ArticleCancer medicine2023

Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.

Dan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.